ABSTRACT
3
Developed in 1993, tigecycline is a semisynthetic analogue of earlier tetracyclines and 32 represents the first member of glycylcyclines. It generally exhibits bacteriostatic activity against a 33 wide spectrum of aerobic and anaerobic bacteria, including multidrug-resistant (MDR) organisms, 34 but it consistently shows little or no activity against Pseudomonas aeruginosa (6, 8, 11) .
35
Pharmacokinetic studies show that tigecycline produces relatively low mean-steady-state 36 serum concentrations of 0.4 to 0.6 mg/liter with an extensive volume of distribution (7, 18, 19, 32) .
37
Excretion is predominantly biliary and renal only as a secondary pathway, accounting up to 59% 38 and 33% of administered dose, respectively. AcrAB efflux system, RamA, was shown to be overexpressed in tigecycline-resistant strains of K.
52
pneumoniae (25, 26) .
53
The first cautionary report on occurrence of bacteremia caused by tigecycline-non- 
59
We report two cases of emergence of tigecycline resistance in vivo after treatment. In vitro 60 antibiotic susceptibility profiling was performed with the Vitek-2 system (bioMérieux Marcy- recovered before (EC1-3) and after tigecycline-containing regimen (EC4-5); JC-KP 1-4, patient 2-K pneumoniae.
